Back to results
US 12,173,073 B2Granted
Methods of treatment by targeting VCAM1 and MAEA
AssigneeAlbert Einstein College of Medicine
InventorsPaul S. Frenette, Sandra Pinho, Qiaozhi Wei, Sung Kyun Lee
Life of this patent
Estimating the term…
Abstract
Antibodies and antibody fragments that inhibit the activity of vascular cell adhesion molecule 1 (VCAM1) and/or macrophage erythroblast attacher (MAEA) are provided, along with formulations and kits comprising these antibodies and antibody fragments and the use of the disclosed compositions, formulations, and kits to treat cancers, sickle cell disease, and Polycythemia Vera.
Claims10
An antibody or immunogenic fragment thereof comprising
- a heavy chain comprising
- (SEQ ID NO:
- 54)
- SYTMS (CDR1);
- (SEQ ID NO:
- 56)
- EISSGGSYTHYAATVTG (CDR2);
- and
- (SEQ ID NO:
- 58)
- GELY (CDR3)
- and
- a light chain comprising
- (SEQ ID NO:
- 68)
- KASQSLLDRGGKTFFN (CDR1);
- (SEQ ID NO:
- 70)
- LVSKLDS (CDR2);
- and
- (SEQ ID NO:
- 72)
- WQGTHFPWT (CDR3);
- wherein said antibody or immunogenic fragment thereof specifically binds vascular cell adhesion molecule 1 (VCAM1).
21 more elements
An antibody or immunogenic fragment thereof comprising a heavy chain comprising SYAMS (SEQ ID NO:82) (CDR1);
- EISSTGSYTHYPDTVTG (SEQ ID NO:84) (CDR2);
- and GEAL (SEQ ID NO:86) and a light chain comprising KSSHSLLDSYGKTYLN (SEQ ID NO:96) (CDR1);
- LVSKLDS (SEQ ID NO:98) (CDR2);
- and WQGTHFPWT (SEQ ID NO:
- 100) (CDR3);
- wherein said antibody or immunogenic fragment thereof specifically binds vascular cell adhesion molecule 1 (VCAM1).
3 more elements
Dependencies are inferred from the claim text.